Skip to search formSkip to main contentSkip to account menu

arzoxifene

A synthetic, aromatic derivative with anti-estrogenic properties. Similar to the agent raloxifene, arzoxifene binds to and interacts with estrogen… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

LY 353381
arzoxifene hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Prevention: Targeted therapy—anastrozole prevents breast cancer
The recent IBIS-II clinical trial results demonstrate anastrozole reduces breast cancer incidence by 53% in postmenopausal women… 
Review
2013
Review
2013
Breast cancer prevention by antihormones and other drugs: where do we stand?
2012
2012
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene
The Generations trial, a multicenter, placebo-controlled, double-blind trial, compared arzoxifene 20 mg/day and placebo in 9,354… 
2012
2012
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass
ObjectiveThe aim of this study was to report the gynecologic safety findings from the Generations trial, a phase 3 study of the… 
2009
2009
Effects of Arzoxifene on Breast Cancer Incidence in Postmenopausal Women with Osteoporosis or with Low Bone Mass.
Precinical and early clinical data indicate that arzoxifene, a third generation SERM, is more potent and bioavailable than… 
Review
2006
Review
2006
Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
Menopause, regardless of age at onset, is associated with a marked increase in coronary heart disease (CHD) risk. On the basis of… 
2005
2005
Effect of the Selective Estrogen Receptor Modulator Arzoxifene on Repopulation of Hormone-Responsive Breast Cancer Xenografts between Courses of Chemotherapy
Selective inhibition of repopulation of clonogenic tumor cells between courses of chemotherapy has potential to improve the… 
Review
2004
Review
2004
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
The new anti-estrogens, including the selective estrogen receptor modulators (e.g., toremifene, droloxifene, idoxifene… 
Review
2003
Review
2003
Novel therapies for osteoporosis
Osteoporosis remains a significant clinical problem despite effective therapies. Many patients cannot or will not take currently… 
Review
2002
Review
2002
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)